Trial Profile
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2023
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary) ; Treprostinil (Primary) ; Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms EXPEDITE
- Sponsors United Therapeutics Corporation
- 28 Aug 2023 Results (n=29) assessing the effect of short course of parenteral treprostinil therapy in right-sided cardiac structural and functional parameters after a short course of parenteral treprostinil, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
- 24 May 2023 Results (n=29) presented at the 119th International Conference of the American Thoracic Society.
- 18 Apr 2023 According to an United Therapeutics Corporation Media Release, results from this trial will be presented at the American Thoracic Society (ATS) International Conference 2023.